MarketPulse

European Commission

3 articles
BenzingaBenzinga··Prnewswire

Soligenix Wins EU Orphan Status for Behçet's Disease Drug SGX945

Soligenix's dusquetide (SGX945) receives EU orphan drug designation for Behçet's Disease, backed by Phase 2a data showing 40% ulcer reduction with no adverse events.
SNGXrare diseaseclinical trial
BenzingaBenzinga··Akanksha Bakshi

Amentum Lands $112M EU Nuclear Cleanup Contract Across Four Nations

Amentum wins $112M EU nuclear decommissioning contract spanning Italy, Germany, Belgium, Netherlands with two-year initial term plus potential six-year extensions.
RWJAMTMIJSSLYVvaluationtechnical analysis
GlobeNewswire Inc.GlobeNewswire Inc.··X4 Pharmaceuticals, Inc.

EMA Committee Backs Mavorixafor for WHIM Syndrome, First European Therapy

EMA committee endorses mavorixafor (XOLREMDI) for WHIM syndrome treatment, marking first approved therapy in Europe. Final Commission approval expected Q2 2026.
XFORWHIM syndromemavorixafor